SecBot SecBot
8-K ·Filed Aug 31, 2026

TELA

TELA Bio, Inc.
MIXED
Impact 6/10
Horizonweeks Processed2mo ago SEC0001104659-26-103548
8-K material event: Items 2.05
Actionable Insight ◆ Mixed

The $17M annual savings relative to a $31M market cap is a significant cost restructuring that could meaningfully extend the company's cash runway into 2028. However, the simultaneous CFO/COO departure adds execution risk. Monitor the Q3 2026 earnings call (early November) for revenue trajectory and updated guidance to assess whether the cost cuts are sufficient to drive profitability.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$0.7380
T+0 close · Aug 31, 2026 · via day close
Latest settled
+68.02%
T+20 · $1.24 · next T+60 in 7d
Vs SPY
+68.21%
α at T+20
Latest observation
+31.84%
T+52 · FF3 residual α
  1. T+0 · Aug 31 $0.7380entry
  2. T+1 · 3mo ago +7.22%α +7.91% · $0.7913
  3. T+5 · 2mo ago +12.48%α +12.62% · $0.8301
  4. T+20 · 7w ago +68.02%α +68.21% · $1.24
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TELA Bio announced a strategic cost reduction initiative including a 20% workforce reduction (201 to 160 employees) and streamlining of external resources, expected to reduce annual operating expenses by $17.0 million (18%) and extend cash runway into 2028. Simultaneously, CFO/COO Roberto Cuca stepped down effective August 31, 2026, with CEO Heather Getz assuming the principal financial officer role. The company expects a one-time restructuring charge of approximately $1.5 million in Q3 2026.

Key Facts

  • Workforce reduction of approximately 20%, from 201 to 160 full-time employees
  • Expected annual operating expense reduction of $17.0 million (18%)
  • One-time restructuring charge of approximately $1.5 million in Q3 2026
  • CFO/COO Roberto Cuca stepped down effective August 31, 2026; departure treated as termination without cause
  • CEO Heather Getz appointed as principal financial officer
  • Cost reduction expected to extend cash runway into 2028
  • Restructuring substantially completed during Q3 2026

Financial Impact

Annual operating expense reduction of $17.0 million (18% of current expenses) against a $31M market cap; one-time cash charge of $1.5 million in Q3 2026

operating expensescash runwayheadcount

Risk Factors

  • Execution risk on achieving the full $17M annual savings without disrupting core operations
  • CFO/COO departure may signal deeper organizational challenges or accounting concerns
  • Workforce reduction could impact sales momentum and product innovation
  • Company remains pre-profitability; revenue growth is critical to validate the restructuring

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-103548
Document: tm2624299d1_ex99-1.htm0001104659-26-103548
Document: 0001104659-26-103548-index-headers.html0001104659-26-103548
Document: 0001104659-26-103548-index.html0001104659-26-103548
Document: 0001104659-26-103548.txt0001104659-26-103548

Track record

20 reports on TELA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +18.61% at T+5 after the Aug 10, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
  4. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  5. Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  6. Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
  7. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
  8. Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
  9. Aug 31, 202611w ago 8-K Mixed 6/10 Viewing Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
  10. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026